Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | PTPRA | P18433 | 1/20 | 0.51 |
| ▸ | PTPRB | P23467 | 1/20 | 0.51 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CASP6 | P55212 | 3/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401976 | 0.95 | CYP1A2 (0.53) | SNCACYP2C9CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL1902549 | 0.95 | CYP1A2 (0.53) | SNCACYP2C9CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL2899556 | 0.87 | HSD17B10 (0.50) | SNCACYP2C9CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL2899953 | 0.87 | HSD17B10 (0.50) | SNCACYP2C9CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL31255683 | 0.86 | CASP6 (0.58) | SNCACYP2C9CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL429785 | 0.86 | CASP6 (0.58) | SNCACYP2C9CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL304050 | 0.86 | SNCA (0.65) | SNCACYP2C9CYP2C19HSD17B10TSHR | |
| SCHEMBL29857297 | 0.86 | SNCA (0.65) | SNCACYP2C9CYP2C19HSD17B10TSHR | |
| SCHEMBL1556 | 0.86 | SNCA (0.65) | SNCACYP2C9CYP2C19HSD17B10TSHR | |
| SCHEMBL29357423 | 0.86 | SNCA (0.65) | SNCACYP2C9CYP2C19HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313037-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | MapLight Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3698791-B1 | INTRANASAL COMPOSITION COMPRISING BETAHISTINE | OTOLANUM AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023180345-A1 | TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023135260-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-07-20 | — | — | WO | disclosed |
| EP-4196090-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NEUROACTIVE STEROID AND USE THEREOF | Brii Biosciences, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023056102-A1 | NOVEL PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | ATAI Life Sciences AG (DE) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022204399-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | MAPLIGHT THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022040216-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NEUROACTIVE STEROID AND USE THEREOF | BRII BIOSCIENCES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021025985-A1 | METHODS OF TREATING SUBSTANCE ABUSE DISORDER, DYSPNEA, TINNITUS, AND CHILD AND ADOLESCENT DEPRESSION | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| EP-3698791-A1 | INTRANASAL COMPOSITION COMPRISING BETAHISTINE | Otolanum AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| WO-2013060881-A1 | PYRIDOPYRIMIDINES AND THEIR THERAPEUTIC USE | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-05-02 | — | — | WO | disclosed |
| EP-2270002-A1 | Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg (NL) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010146173-A1 | QUINAZOLINE DERIVATIVES AS HISTAMINE H4-RECEPT0R INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-12-23 | — | — | WO | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| EP-2238119-A1 | QUINAZOLINES AND RELATED HETEROCYCLIC COMPOUNDS, AND THEIR THERAPEUTIC USE | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg (NL) | 2010-10-13 | — | — | EP | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| WO-2009083608-A1 | QUINAZOLINES AND RELATED HETEROCYCLIC COMPOUNDS, AND THEIR THERAPEUTIC USE | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2009-07-09 | — | — | WO | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
| EP-2044027-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | SNCA 2879/4885CYP2C9 143/4885CYP1A2 373/4885 |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | HRH4, HRH3, HRH2 | SNCA 3677/4885CYP2C9 635/4885CYP1A2 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.